Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer

Future Oncol. 2015 Nov;11(22):3091-8. doi: 10.2217/fon.15.249. Epub 2015 Sep 18.

Abstract

Aim: A higher Gleason score was associated with a lower tumor urotensin II receptor (UTII-R) expression in prostate cancer patients.

Methods: A retrospective review of formalin-fixed paraffin-embedded tumor tissue derived from those who had prostatectomy and matching biopsy specimens was conducted at six Institutions. UTII-R expression was evaluated on biopsy by immunohistochemistry.

Results: A total of 58 subjects undergoing radical prostatectomy were included. At multivariate analysis, low UTII-R expression was a significant predictor of Gleason upgrading, with an odds ratio of 10.3 (95% CI: 1.55-68.4), and of pathology upstaging, with an odds ratio of 11.1 (95% CI: 1.23-100.48).

Conclusions: UTII-R expression on biopsy was associated with Gleason upgrading and pathology upstaging in prostate cancer patients.

Keywords: Gleason score; prostate cancer; urotensin II receptor.

MeSH terms

  • Aged
  • Biopsy
  • Disease Progression
  • Humans
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Staging
  • Preoperative Period*
  • Prostatectomy
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / metabolism*
  • Prostatic Neoplasms / pathology*
  • Prostatic Neoplasms / surgery
  • Receptors, G-Protein-Coupled / genetics
  • Receptors, G-Protein-Coupled / metabolism*
  • Retrospective Studies

Substances

  • Receptors, G-Protein-Coupled
  • UTS2R protein, human